TheStreet's Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza, but has dropped off after the FDA delayed its decision. Cramer says Visa is getting "clubbed" and he needs to look into the credit card companies a little more, but FireEye is a "high-flyer." Finally, Cramer says he is unsure if Linn Energy's recently-declared dividend is safe. Send your Twitter questions to #CramerQ on Monday mornings.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind